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Accepted 13 January 2016Background: Total knee arthroplasty (TKA) is a common procedure resulting in signiﬁcant post-operative pain.
Percutaneous cryoneurolysis targeting the infrapatellar branch of the saphenous nerve and anterior femoral cu-
taneous nerve could relieve post-operative knee pain by temporarily blocking sensory nerve conduction.
Methods: A retrospective chart review of 100 patients who underwent TKA was conducted to assess the value of
adding perioperative cryoneurolysis to amultimodal painmanagement program. The treatment group consisted
of the ﬁrst 50 patients consecutively treated after the practice introduced perioperative (ﬁve days prior to
surgery) cryoneurolysis as part of its standard pain management protocol. The control group consisted of the
50 patients treated before cryoneurolysis was introduced. Outcomes included hospital length of stay (LOS),
post-operative opioid requirements, and patient-reported outcomes of pain and function.
Results: A signiﬁcantly lower proportion of patients in the treatment group had a LOS of ≥2 days compared with
the control group (6% vs. 67%, p b 0.0001) and required 45% less opioids during the ﬁrst 12 weeks after surgery.
The treatment group reported a statistically signiﬁcant reduction in symptoms at the six- and 12-week follow-up
comparedwith the control group andwithin-group signiﬁcant reductions in pain intensity and pain interference
at two- and six-week follow-up, respectively.
Conclusions: Perioperative cryoneurolysis in combination with multimodal pain management may signiﬁcantly
improve outcomes in patients undergoing TKA. Promising results from this preliminary retrospective studywar-
rant further investigation of this novel treatment in prospective, randomized trials.
Level of evidence: III
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Total knee arthroplasty (TKA) is a very common surgery for ad-
vanced osteoarthritis of the knee that is unresponsive to conservative
treatments. There are approximately 600,000 knee replacements per-
formed each year, and this number is expected to increase in future
years [1]. Although knee replacements usually are very successful in
the long term, patients often experience a signiﬁcant amount of pain
during the immediate post-operative period, which can be a major hin-
drance to effective rehabilitation and restoration of function following
surgery.
Perioperative pain control has been the focus of considerable atten-
tion in recent years. Traditionally, narcotic pain medications have been
used to control pain; however, their well-known side effects, such as
nausea, emesis, ileus, and dependence, can slow down recovery [2]. Re-
cently, multimodal pain management has been promoted to improvec Surgery, 1542 Tulane Avenue,
.: +1 504 568 4680 (Voice);
. This is an open access article underperioperative pain control while minimizing the risk of adverse events
in the American Society of Anesthesiologists practice guidelines for
acute pain management [3]. Multimodal pain management protocols
implemented after total hip and knee arthroplasty (THA and TKA)
have been shown to result in better pain control andpatient satisfaction,
lower overall narcotic consumption, shorter hospital stays, improved
function, and fewer complications [4].
The use of cold as an analgesic dates back to the days of Hippocrates
and the ancient Egyptians [5]. Recent work has shown the effect of
cryoneurolysis on peripheral sensory nerve function. Barnard demon-
strated that cryoneurolysis applied to the terminal branches of the tri-
geminal nerve in rats causes degeneration distal to the site of freezing
without disruption of the anatomical architecture followed by structural
regeneration of the nerve at about sixweeks of post-injury and recovery
of normal sensation in two to fourmonths [6]. Histological studies have
shown that treatment of nerves with temperatures from −20° to
−60 °C results in Wallerian degeneration [6], which occurs distal to
the site of injury and involves loss of the relative continuity of the
axon and its covering of myelin, but preservation of the surrounding
endoneurial, perineurial, and epineurial structure, which allows for nor-
mal axonal regeneration and remyelination [6]. Functional recovery ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Baseline clinical characteristics.
Variable Control Treatment p value
KOOS
Activities of daily living N 46 49 0.82
Mean (SD) 41.07 (21.97) 40.14 (17.51)
Pain N 46 49 0.57
Mean (SD) 36.04 (20.82) 38.18 (15.38)
Quality of life N 44 49 0.29
Mean (SD) 22.16 (23.42) 17.86 (15.34)
Sports and rec N 31 37 0.70
Mean (SD) 25.58 (31.54) 22.68 (29.62)
Symptoms N 46 49 0.53
Mean (SD) 44.11 (19.32) 41.80 (16.74)
Oxford Knee Score N 46 46 0.97
Mean (SD) 18.72 (10.30) 18.78 (8.45)
PROMIS
Anxiety N 18 41 0.32
Mean (SD) 58.78 (12.88) 55.45 (11.11)
Depression N 19 45 0.5
Mean (SD) 51.03 (11.17) 49.14 (9.71)
Fatigue N 18 44 0.85
Mean (SD) 53.23 (8.74) 52.73 (10.07)
Pain interference N 18 46 0.69
Mean (SD) 65.27 (8.23) 66.13 (7.60)
Pain intensity N 18 46 0.93
Mean (SD) 6.83 (2.90) 6.89 (2.16)
Sleep disturbances N 17 41 0.16
Mean (SD) 54.45 (9.41) 51.14 (7.48)
Social satisfaction N 18 43 0.86
Mean (SD) 39.83 (10.63) 40.42 (12.10)
Physical function N 19 43 0.12
Mean (SD) 35.49 (6.49) 33.05 (5.17)
SF-12 mental component N 30 41 0.01
Mean (SD) 42.77 (12.28) 50.00 (10.43)
SF-12 physical component N 30 41 0.22
Mean (SD) 30.76 (7.12) 28.77 (6.41)
WOMAC
Function N 50 49 0.99
Mean (SD) 41.92 (22.10) 41.90 (17.00)
Pain N 50 49 0.74
Mean (SD) 41.20 (22.69) 42.55 (17.74)
Stiffness N 50 49 0.39
Mean (SD) 40.82 (26.19) 36.94 (17.03)
KOOS= Knee Injury and Osteoarthritis Outcome Score; PROMIS= Patient-reported Out-
comes Measurement Information System; SD = standard deviation; SF-12 = 12-item
Short Form Health Survey; WOMAC = Western Ontario and McMaster Universities
Arthritis Index.
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months after cryoneurolysis depending on the distance of the axon inju-
ry site to the target site and rate of axon regrowth [6].
In a preclinical study, Hsu and Stevenson observed signiﬁcant axonal
regeneration and remyelination with concurrent elimination of macro-
phage inﬁltration and via histological examination of nerves eight
weeks following cryoneurolysis and complete axonal regeneration by
16 weeks post-treatment [7]. Consistent with these ﬁndings,
cryoneurolysis of peripheral sensory nerves has been shown to be efﬁ-
cacious in attenuating pain symptoms in patients with clinical condi-
tions including trigeminal neuralgia, neuroma, and post-thoracotomy
pain [5,8–12], with pain relief ranging from a couple of months to a
few years [10,13].
Neuropathic knee pain is an important source of post-operative pain
[13]. Percutaneous cryoneurolysis directed at sensory nerves that inner-
vate the knee is a new option for reducing TKA post-operative pain [13].
Cryoneurolysis treatment of knee pain targets the infrapatellar branch
of the saphenous nerve (ISN) and anterior femoral cutaneous nerve
(AFCN), which lie in a predictable and superﬁcial location as they ap-
proach the knee. The ISN and AFCN provide sensory innervation around
the anterior kneewithnomotor involvement. After extensive use by the
senior author in treatment of knee osteoarthritis pain, he began using
this new treatment to improve post-operative outcomes following
TKA. This study was conducted to evaluate whether perioperative
cryoneurolysis, in combination with a standard multimodal pain regi-
men, would shorten hospital stays, decrease narcotic medication use,
and improve patient-reported outcomes.
2. Materials & methods
2.1. Patient selection and methods
This was a retrospective chart review of 100 patients who
underwent TKA by a single surgeon at a university-based orthopedic
practice from 2011 to 2014. The treatment group (cryoneurolysis plus
multimodal pain management) included the ﬁrst 50 patients who
were treated with cryoneurolysis after March 31, 2014, when the prac-
tice began administering perioperative cryoneurolysis to all TKA pa-
tients as part of its standard perioperative pain management protocol.
This was the only appreciable change in practice and all other aspects
of the treatment protocol (e.g., intraoperative and post-operative pain
protocol, surgical technique, implant selection) remained the same.
The control group consisted of the ﬁrst 50 patients who were treated
with multimodal pain management alone, preceding the introduction
of the cryoneurolysis plus multimodal pain management regimen,
whohad completed theWestern Ontario andMcMaster Universities Ar-
thritis Index (WOMAC).
Among the 100 patients included in the study, 70 were females and
30 males. As shown in Table 1, the treatment and control groups were
similar in terms of gender (p = 0.66), age (p = 0.24), and body mass
index (BMI) (p = 0.26). There were no overall signiﬁcant differences
between groups on baseline patient-reported outcome measures
(Wilks' F-test, p = 0.73, Table 2). The treatment group received
cryoneurolysis of the AFCN and ISN ﬁve days prior to surgery in addition
to the standard preoperative multimodal pain management program.Table 1
Patient demographics.
Control
(N = 50)
Treatment
(N = 50)
p value
Gender 0.66
Male, N (%) 14 (46.7) 16 (53.3)
Female, N (%) 36 (51.4) 34 (48.6)
Age (years), mean (SD) 66.4 (9.4) 68.5 (8.2) 0.24
Body mass index (kg/m2), mean (SD) 30.9 (5.7) 32.1 (5.3) 0.26Cryoneurolysis was administered using a novel handheld device, iovera
(Myoscience, Fremont California, Figure 1), which was FDA approved
(K100447 and K133453) in 2012 to produce “lesions in peripheral ner-
vous tissue by the application of cold to the selected site for the blocking
of pain.” This device converts liquid nitrous oxide into a gas, creating
temperatures of−125 °F along three hollow closed tip short needles
(27 gauge, 6 mm long), introduced percutaneously at a target site, to
produce a ﬁve millimeter cold zone (ice ball) under the skin. Ice ball
contact with the target nerve causes Wallerian degeneration, creating
axonotmesis while maintaining the original surrounding anatomy
(maintaining the scaffold) to allow predictable regrowth of the axon
along the original epineurium and endoneurium. The maximum cold
temperature produced by the device has no known permanent risks be-
cause the original structural scaffold of the nerve is preserved. There are
limited transient side effects, such as bruising and tendernesswhere the
needles are inserted.
Treatments were done in the ofﬁce ﬁve days before planned TKA.
The AFCN and ISN and their branches were targeted along two treat-
ment lines. The AFCNwas targeted approximately 70mm above the su-
perior pole of the patella along a horizontal line thewidth of the patella.
The AFCN lies within the fascia overlying the quadriceps tendon deep to
the subcutaneous fat (Figure 2). The ISN was targeted approximately
50 mm medial to the patella tendon (Figure 3) along a longitudinal
line from the inferior pole of the patella and tibial tubercle. The ISN
Figure 1. Iovera cryoneurolysis device.
Figure 2. Anterior femoral cutaneous nerve (AFCN) treatment line (published with
permission fromMyoscience, Inc.).
Figure 3. Infrapatellar branch of saphenous nerve (ISN) treatment line (published with
permission from Myoscience, Inc.).
525V. Dasa et al. / The Knee 23 (2016) 523–528lies along the joint capsule deep to the subcutaneous fat. Using these an-
atomical landmarks, treatment lines were drawn on the patient's knee.
Approximately ﬁve cubic centimeters of one percent of lidocaine using a
25 gauge needle was injected subcutaneously along the treatment lines
to provide cutaneous analgesia.
A treatment cycle consists of a period of cooling thenwarming of the
needles, lasting approximately 50 s. Once a treatment cycle was com-
plete, the needles were then introduced along the next section of the
treatment line. Each line required approximately six treatment cycles
to cover the length of the treatment line.When the ice ball encountered
the target nerve, most patients provided sensory feedback (e.g., burning
or tingling sensations) as Wallerian degeneration was induced; this
feedback conﬁrmed that the treatment was being applied to the area
in which the target nerve traverses. This subjective sensation was difﬁ-
cult to record or quantify. Total time to freeze both nerves and their
branches was approximately 15min. The technique is fairly straightfor-
ward and intuitive. Although there may be a limited learning curve of
one or two treatments, the authors did not notice any appreciable difﬁ-
culty in conducting the ﬁrst few treatments compared with later in the
course of the study.
Both groups received the same preoperative, intraoperative, and
post-operative care with exception of the additional perioperative
cryoneurolysis treatment received by the treatment group. The multi-
modal pain regimenwas administered as follows. Preoperatively during
the admission process, patients received one dose of acetaminophen
650 mg, pregabalin 300 mg, and celecoxib 200 mg. Intraoperatively,
patients received decadron of 10 mg and a periarticular injection
of bupivacaine with epinephrine administered in two phases.
Approximately 30 min before the surgery, all patients received spinal
anesthesia and a single-injection femoral nerve or adductor block
(20 ml ropivicaine 0.2%, decadron one milligram, clonidine 25 mcg,
526 V. Dasa et al. / The Knee 23 (2016) 523–528and epinephrine 1:200,000). No patient received general anesthesia.
Prior to incision, bupivacaine with epinephrine was injected along the
anterior and medial knee targeting the AFCN and ISN nerves within
the deep fascia. During the surgery, after bony cuts were complete, lam-
ina spreaders were used in ﬂexion to expose the posterior capsule, and
two 10 cm3 syringes of bupivacainewith epinephrinewere injected into
the posterior,medial, and lateral capsules. Post-operatively in the hospi-
tal, patients received acetaminophen of 650 mg every eight hours,
celecoxib 200mg twice daily, pregabalin 150mg twice daily, and oxyco-
done 10 mg every six hours as needed.
All patients underwent navigated posterior stabilized TKA using
an anterior midline incision and medial parapatellar arthrotomy. No
quadriceps-sparing procedures were performed. Patients aged
b65 years received a Zimmer® NexGen® Complete Knee Solution
(Zimmer, Inc., Warsaw, IN) implant with a monolithic uncemented
tibial component; those aged ≥65 years received either a Zimmer®
NexGen® Complete Knee Solution or U2 Knee™ System (United
Orthopedic Corporation, Irvine, CA) implant with traditional cemented
components. All surgeries were performed by the senior author (VD),
a board-certiﬁed orthopedic surgeon who had completed a fellowship
in adult reconstruction.
Narcoticswere prescribed in the hospital with a prn dosing regimen.
The treating surgeon used a standard opioid prescription protocol for all
patients. Patients received a prescription for 84 pills (two weeks) of
oxycodone-acetaminophen 10/325 mg at discharge. All patients were
seen at two, six, and 12 weeks following surgery. Only if requested, pa-
tients could receive a prescription for 120 pills (one-month supply) of
oxycodone-acetaminophen 10/325 at the two-week follow-up visit
and 90 pills (one-month supply) of oxycodone-acetaminophen 10/
325 at the six-week visit. No narcotics were given at the 12-week
visit. All prescribed narcoticswere converted intomorphine equivalents
using an opioid dose calculator where one milligram of hydrocodone
and one milligram of oxycodone were equal to one milligram and
1.5 mg of morphine, respectively.
Patient-reported outcome measures, including the WOMAC, Knee
injury and Osteoarthritis Outcome Score (KOOS), Oxford Knee Score,
12-item Short Form Health Survey (SF-12) and Patient-reported Out-
comes Measurement Information System (PROMIS), were completed
at baseline (precryoneurolysis) and at the two-, six- and 12-week
post-operative visits. In 2013, the clinic switched from using the
WOMAC to the KOOS questionnaire; WOMAC scores were calculated
for patients who completed the KOOS questionnaire based on their re-
sponses to the KOOS survey. Hospital discharge criteria included the7
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Figure 4. Length of hospital stay inability to walk 50 ft with a walker or crutches, get in and out of bed
and on and off a toilet independently, and pain adequately controlled
with oral medications. Patient medical records were reviewed to deter-
mine the incidence of any complications or side effects associated with
cryoneurolysis. Patients were discharged directly to home with outpa-
tient physical therapy beginning the following day. An Institutional Re-
view Board approved the study protocol.
3. Statistical analysis
Statistical analyses were conducted using SAS software (version 9.4,
SAS Institute, Inc., Cary, NC). Differences between groups on demo-
graphics and baseline characteristics were examined using chi-square
tests (categorical variables) or Wilks' F test (continuous patient-
reported outcomes). Efﬁcacy endpoints were length of hospital stay
(LOS), mean cumulative narcotic use in morphine equivalent units,
and mean scores on the KOOS, WOMAC, Oxford Knee Score, SF-12 and
PROMIS. LOS was categorized into three levels as follows: 0 (0 days),
one (one day), and two (≥2 days). Pearson's chi-square test examined
differences between the control and treatment groups on LOS. A general
linear model, with age and gender, and BMI as covariates and allowing
for different variances in the two groups, was used to compare differ-
ences in mean cumulative narcotic use between the groups using the
Satterthwaite adjusted F-test. Mean change from baseline to two-, six-
and 12- week follow-up on the KOOS, WOMAC, Oxford Knee Score,
SF-12 and PROMIS were compared using a repeated measures analysis
that allowed for modeling dependencies between observations within
subjects with age, gender, and BMI as covariates, the Kenward–Roger
adjusted F-test as the test for statistical signiﬁcance, and the Tukey–
Kramer adjustment for multiple comparisons.
4. Results
A signiﬁcantly greater proportion of patients in the control group had a longer LOS
than the treatment group (Figure 4). Speciﬁcally, 67.3% (33/49) of patients in the control
group had a LOS of ≥2 days compared with 6.1% (3/49) in the treatment group
(p b 0.0001). Similarly, a higher proportion of patients in the treatment group had a LOS
of 0 days (44.9% vs. 14.3%) or one day (49.0% vs. 18.4%). The mean ± SD (range) for LOS
was 1.7 ± 1.01 (0 to seven) days for the control group, and 0.8 ± 1.14 (0 to ﬁve) days
for the treatment group. Statistical analysis was based on median values. The mean ±
SE cumulative morphine use during the 12 weeks following surgery was signiﬁcantly
lower for the treatment versus control group (2069.12 ± 132.09 mg vs. 3764.42 ±
287.95mg, p b 0.0001). As shown in Figure 5, the treatment groupused45% lessmorphine
equivalent narcotics than the control group during the 12 weeks following surgery after
adjusting for age, gender, and BMI.7
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Figure 5. Average cumulative morphine equivalent prescribed at 12 weeks post-TKA in the control and treatment groups. (p b 0.0001). Error bars are at 95% CI.
527V. Dasa et al. / The Knee 23 (2016) 523–528Table 3 (see Supplemental online Appendix) shows the patient-reported outcomes at
the two-, six-, and 12-week post-operative visits. The treatment group achieved statisti-
cally signiﬁcantly greater reductions in the KOOS symptoms subscale score from baseline
to the six- and 12-week post-operative visits than control group (p= 0.0037 at six weeks
and 0.0011 at 12weeks). These differences were attenuated but remained statistically sig-
niﬁcant after adjusting for age, gender, and BMI. Results also indicated that the treatment
group experienced less pain.
When comparing differenceswithin groups to baseline at twoweeks post-surgery, the
treatment group had signiﬁcantly reduced PROMIS pain intensity scores (p b 0.0001)
whereas the control group showed no signiﬁcant change (p = 0.176) from baseline.
PROMIS pain interference, a scale that quantiﬁes the extent to which pain interferes with
daily activities, was signiﬁcantly decreased from baseline to six weeks in the treatment
group (p = b0.0001), but not in the control group (p = 0.067).
No complicationswere noted related to cryoneurolysis treatment. Therewere no local
infections, excess bleeding, or local soft tissue necrosis encountered within the surgical
ﬁeld. Patients did not complain of persistent numbness or other neurologic effects at
their three-month post-operative visit. The most common side effect was local bruising
at the site of treatment, which had no clinical impact.
5. Discussion
The use of traditional nerve blocks has been proven effective
in reducing post-operative pain and producing better long-term knee
scores [14]. To our knowledge, this is the ﬁrst study to show that
cryoneurolysis administered prior to TKA in combination with a stan-
dard multimodal pain management regimen improves outcomes com-
pared with standard multimodal pain management alone. Patients
who received perioperative cryoneurolysis targeting the AFCN and ISN
had a signiﬁcantly shorter LOS, were prescribed signiﬁcantly less
opioids during the ﬁrst 12weeks post-operatively, and had signiﬁcantly
less knee symptoms than patients who did not receive perioperative
cryoneurolysis. The means did show improved scores across all
categories; however, given the natural amount of variation between
patients, these results only achieved statistically signiﬁcant between-
group differences in KOOS symptoms and PROMIS pain intensity and
pain interference when compared with baseline in the treatment
group but not the control group. These results are consistent anecdotal
reports by our hospital and outpatient physical therapists, who noticed
greater patient satisfaction and more productive physical rehabilitation
sessions after preoperative cryoneurolysis was instituted as part of the
multimodal pain regimen.
The ability to decrease hospital LOS following TKA should substan-
tially reduce costs for hospitals and payers. In the present study, only
six percent of patients treated with cryoneurolysis prior to surgery
stayed in the hospital for two or more days compared with 67% of pa-
tients who did not receive this treatment. Similarly, almost half of pa-
tients treated with cryoneurolysis were discharged on the same day of
surgery compared with only 14% in the control group. The shorter LOS
for patients who received adjunctive perioperative cryoneurolysis may
be due to 1) better local control of pain and a reduced need for proximalnerve blocks that can impair motor function and delay discharge and
2) reduced use of opioids to control pain during the immediate post-
operative period, which allows for earlier ambulation and achievement
of function required for discharge. Earlier ambulation following TKA has
been associated with a shorter LOS and lower hospitalization costs [15].
Shortening the patient's hospital stay may also help lower costs
by reducing the risk of developing hospital-acquired infections, which
are strongly correlated with LOS [16,17], and add to the cost of
hospitalization.
Patients who received cryoneurolysis in addition to standard multi-
modal pain management were prescribed 45% less opioids during the
ﬁrst 12weeks of recovery following TKA than thosewho did not receive
cryoneurolysis. Reduced opioid requirements to manage pain has im-
portant beneﬁts, including decreased health care utilization (ER visits
and ofﬁce phone calls) and a lower risk of opioid-related side effects
(e.g., nausea, constipation/ileus, sedation, dizziness, vomiting, physical
dependence, tolerance, and respiratory depression) [2,18]. The signiﬁ-
cant reduction in narcotic use observed in the present study conﬁrms
that the innervation and pain generators surrounding the incision and
anterior knee targeted in the present study are a major source of pain
following TKA, and suggests that soft tissue innervation originating
from the femoral nerve, rather than bony and posterior pain innervated
by the geniculate nerves originating from the tibial nerve, is the major
source of post-operative pain. However, future studies should evaluate
whether targeting the geniculate nerves in addition to the AFCN and
ISN provides further reduction in pain.
This study had several limitations, including its retrospective,
nonrandomized nature, and lack of blinding of patients and investiga-
tors, which may have biased results and limits the generalizability of
ﬁndings. Selection bias may have inﬂuenced results as the control
groupwas comprised of the ﬁrst 50 patients with completeWOMAC re-
sponses treated prior to the initiation of preoperative cryoneurolysis.
These patients may have been different from less compliant patients
who did not complete the questionnaire and were excluded from the
control group. In addition, differences between the control and treat-
ment groups may be attributable to history or other confounding fac-
tors, rather than the study intervention. Because the treatment group
underwent TKA more recently than the control group, and there has
been a trend towards reducing post-operative LOS in the U.S. [19], it is
possible that the shorter LOS observed in the treatment group may be
an artifact of history. However, the U.S. hospital mean LOS decreased
by just 0.2 days from 2003 to 2012 [19]. Thus, it seems unlikely that his-
torical trends can explain the dramatically lower LOS observed in the
treatment group compared with the control group (mean of 0.8 days
vs. 1.7 days).
Patients' and surgeons' awareness of which patients received
cryoneurolysis may have contributed to some of the improved
528 V. Dasa et al. / The Knee 23 (2016) 523–528outcomes in the treatment group, including self-reportedmeasures and
LOS. Although the surgeon made the ultimate determination for dis-
charge, this decision was based on the patient's ability to meet certain
objectively-measured physical therapy metrics, which reduces the like-
lihood that discharge decisionswere biased. Further, while patients' and
surgeons' expectations may have favorably inﬂuenced outcomes in the
treatment group, it is unlikely that these expectations were solely re-
sponsible for the dramatic reduction in LOS and post-operative opioid
requirements observed in this group. There were missing data on
PROMS for both study groups, due to inconsistent completion of ques-
tionnaires, although missing PROM data was more commonly seen in
the control group as the ofﬁce improved its efforts to encourage patient
completion of surveys over time. The lack of signiﬁcant differences be-
tween the treatment and control groups on PROM's may be due in
part to unequal and small sample sizes for these measures.
In conclusion, adding cryoneurolysis to a multimodal perioperative
pain management protocol in patients undergoing TKA may help de-
crease hospital LOS, reduce post-operative opioid requirements, and
improve knee symptoms and pain. Adequately powered prospective
randomized studies are needed to validate the ﬁndings of this prelimi-
nary report.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.knee.2016.01.011.
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